Zai Lab's (HKG:9688) net loss narrowed to $81.7 million in the fourth quarter of 2024 from $95.4 million in the year-ago period, according to a Thursday filing with the Hong Kong Exchange.
Loss per share at the biopharmaceutical company narrowed to $0.08 from $0.10 in the previous year. Analysts at Visible Alpha estimated loss per share at $0.07.
Revenue grew 66% to $109.1 million from $65.8 million a year earlier. Visible Alpha analysts forecasted revenue at $105 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.